SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Potential Offer

6 Sep 2010 15:14

RNS Number : 2239S
Silence Therapeutics PLC
06 September 2010
 



 

 

FOR IMMEDIATE RELEASE

 

Potential Offer

 

London, 6 September, 2010 - Silence Therapeutics plc (AIM: SLN) notes the recent share price movement and announces that it has received an approach which may or may not lead to an offer for the Company. A further announcement will be made in due course.

 

For further information, please contact:

 

Silence Therapeutics

Phil Haworth, CEO +1 (650) 855-1514

p.haworth@silence-therapeutics.com

NOMAD

Nomura Code Securities

Richard Potts / Jonathan Senior

+44 20 7776 1200

 

European media and investor enquiries:

M:Communications +44 20 7920 2342

Mary-Jane Elliott / Emma Thompson

 

US media and investor enquiries:

Vida Communication +44 (415) 675-7400

Tim Brons (media)

tbrons@vidacommunication.com 

or

Stephanie Diaz (investors)

sdiaz@vidacommunication.com

 

The City Code on Takeovers and Mergers (the "City Code")

 

1) Rule 2.10 of the City Code

 

In accordance with Rule 2.10 of the City Code, the Company confirms that it has 279,891,452 ordinary shares of 1p each in issue under the ISIN code GB0008433350.

 

2) Disclosure requirements of the Takeover Code (the "Code")

 

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any paper offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any paper offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any paper offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a paper offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

 

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any paper offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any paper offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

 

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a paper offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

 

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4). Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
SPMZQLFBBKFBBBK
Date   Source Headline
20th Jan 20203:23 pmRNSHolding(s) in Company
13th Jan 20208:37 amRNSHolding(s) in Company
9th Jan 202010:04 amEQSEdison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)
9th Jan 20208:43 amRNSHolding(s) in Company
8th Jan 20209:11 amRNSHolding(s) in Company
7th Jan 202010:12 amRNSHolding(s) in Company
7th Jan 20207:00 amRNSSilence Therapeutics Announces Business Update
27th Dec 20197:00 amRNSHolding(s) in Company
17th Dec 20193:31 pmRNSManagement Change
17th Dec 20197:45 amRNSDirector disclosure
17th Dec 20197:45 amRNSBoard changes
27th Nov 20199:14 amRNSAdditional Listing
22nd Nov 20199:23 amRNSAdditional Listing
13th Nov 20192:45 pmRNSHolding(s) in Company
30th Oct 20193:13 pmRNSAdditional Listing
25th Oct 201910:25 amRNSAdditional Listing
14th Oct 201910:40 amRNSHolding(s) in Company
7th Oct 20197:00 amRNSHoldings in Company
7th Oct 20197:00 amRNSGrant of share options
4th Oct 20195:21 pmRNSDirector/PDMR Shareholding and Additional Listing
3rd Oct 20193:40 pmRNSDirector/PDMR Shareholding
2nd Oct 20195:09 pmRNSDirector/PDMR Shareholding
1st Oct 20196:06 pmRNSDirector/PDMR Shareholding and Additional Listing
30th Sep 20195:09 pmRNSDirector/PDMR Shareholding
24th Sep 20197:00 amRNSFirst research milestone for SLN500
20th Sep 20193:19 pmRNSAdditional Listing
16th Sep 20194:46 pmRNSAdditional Listing
12th Sep 20197:00 amRNSInterim results for six months ended 30 June 2019
27th Aug 20198:28 amRNSHolding(s) in Company
21st Aug 201910:14 amRNSAdditional Listing
19th Aug 20193:15 pmRNSAdditional Listing
15th Aug 20197:00 amRNSNotice of Results and R&D day
13th Aug 20197:00 amRNSAdditional Listing
8th Aug 20194:27 pmRNSAdditional Listing
7th Aug 20191:38 pmRNSAdditional Listing
6th Aug 201912:41 pmRNSAdditional Listing
5th Aug 20197:00 amRNSSilence Therapeutics appoints Jørgen Wittendorff
1st Aug 20194:22 pmRNSHolding(s) in Company
31st Jul 20198:19 amRNSHolding(s) in Company
30th Jul 20195:30 pmRNSAdditional Listing
29th Jul 20197:00 amRNSBoard Appointment
26th Jul 20191:33 pmRNSHolding(s) in Company
25th Jul 201912:26 pmRNSHolding(s) in Company
24th Jul 20198:43 amRNSHolding(s) in Company
23rd Jul 201911:27 amRNSAdditional Listing
19th Jul 20194:35 pmRNSPrice Monitoring Extension
19th Jul 20193:13 pmRNSAdditional Listing
18th Jul 201911:46 amRNSMallinckrodt to make equity investment in Silence
18th Jul 201911:45 amRNSSilence collaboration with Mallinckrodt
16th Jul 201911:46 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.